Home › Companies › MERSANA THERAPEUTICS INC. › 2023-2024
Compiled from SEC Form N-PX filings and MERSANA THERAPEUTICS INC.’s Form 8-K, filed 2024-06-11 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024
Explore MERSANA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are MERSANA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-11 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Willard H. Dere, M.D. | 84,576,414 | 12,733,786 | 104,329 | -- | 8,260,872 | Majority: yes |
| Elect Director: Martin Huber, M.D. | 96,836,592 | 472,410 | 105,527 | -- | 8,260,872 | Majority: yes |
| Proposal 2: Advisory Vote on Executive Compensation The Company's stockholders approved Proposal 2 | 96,316,340 | 984,371 | 113,818 | -- | 8,260,872 | Majority: yes |
| Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm The Company's stockholders approved Proposal 3 | 105,233,670 | 323,020 | 118,711 | -- | -- | Majority: yes |
Source: MERSANA THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-11 — read the filing on EDGAR.
Each item below shows how the 142 asset managers that disclosed a MERSANA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
MERSANA THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Advisory Vote on Executive Compensation The Company's stockholders approved Proposal 2”): 96,316,340 for, 984,371 against, per its Form 8-K filed 2024-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 122,361,236 outstanding shares: 79% for, 0.9% against (80% of the company cast a for/against vote).
The 140 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 19,364,688 | 0 | 0 | 0 | For |
| VR Adviser, LLC | 11,328,000 | 0 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | 0 | 0 | 0 | For |
| State Street | 8,249,587 | 0 | 0 | 0 | For |
| BlackRock | 7,549,488 | 0 | 0 | 0 | For |
| Vanguard | 6,402,647 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 3,046,782 | 0 | 0 | 0 | For |
| Woodline Partners LP | 2,934,622 | 0 | 0 | 0 | For |
| Citadel | 2,642,768 | 0 | 0 | 0 | For |
| Fidelity | 2,630,271 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,346,362 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2,196,111 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 1,863,681 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 1,444,981 | 0 | 0 | 0 | For |
| 5AM Venture Management, LLC | 1,305,000 | 0 | 0 | 0 | For |
| DE Shaw | 1,278,087 | 0 | 0 | 0 | For |
| JPMorgan | 1,095,086 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 1,000,000 | 0 | 0 | 0 | For |
| Northern Trust | 835,343 | 93 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 767,907 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 750,000 | 0 | 0 | 0 | For |
| Invesco | 0 | 606,725 | 0 | 0 | Against |
| Charles Schwab | 591,744 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 548,746 | 0 | 0 | 0 | For |
| Wellington | 483,640 | 0 | 0 | 0 | For |
Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
MERSANA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Martin Huber, M.D.”): 96,836,592 for, 472,410 against, per its Form 8-K filed 2024-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 122,361,236 outstanding shares: 79% for, 0.4% against (80% of the company cast a for/against vote).
The 42 asset managers below cast 99.9% of the shares they voted on this item FOR (19,708,581 for, 14,464 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,218,949 | 0 | 0 | 0 | For |
| BlackRock | 4,058,042 | 0 | 0 | 0 | For |
| State Street | 3,015,686 | 4,719 | 0 | 0 | For |
| Fidelity | 2,416,647 | 0 | 0 | 0 | For |
| JPMorgan | 949,330 | 0 | 0 | 0 | For |
| Equitable | 351,584 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 333,424 | 0 | 0 | 0 | For |
| Charles Schwab | 295,872 | 0 | 0 | 0 | For |
| Invesco | 291,363 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 232,300 | 0 | 0 | 0 | For |
| SEI | 212,020 | 0 | 0 | 0 | For |
| Lincoln Financial | 168,180 | 2,209 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 161,956 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 150,000 | 0 | 0 | 0 | For |
| Voya | 144,037 | 0 | 0 | 0 | For |
| TIAA | 117,317 | 0 | 0 | 0 | For |
| ProShares | 71,514 | 0 | 0 | 0 | For |
| ETF Series Solutions | 57,347 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 54,639 | 0 | 0 | 0 | For |
| John Hancock | 41,953 | 0 | 0 | 0 | For |
| Pacific Life | 41,846 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 40,200 | 0 | 0 | 0 | For |
| Brighthouse | 36,454 | 0 | 0 | 0 | For |
| New York Life | 29,740 | 0 | 0 | 0 | For |
| Nationwide | 29,622 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Combines 2 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
MERSANA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Willard H. Dere, M.D.”): 84,576,414 for, 12,733,786 against, per its Form 8-K filed 2024-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 122,361,236 outstanding shares: 69% for, 10% against (80% of the company cast a for/against vote).
The 42 asset managers below cast 91% of the shares they voted on this item FOR (17,894,798 for, 1,828,247 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,207,238 | 11,711 | 0 | 0 | For |
| BlackRock | 4,058,042 | 0 | 0 | 0 | For |
| State Street | 2,976,654 | 43,751 | 0 | 0 | For |
| Fidelity | 2,405,947 | 10,700 | 0 | 0 | For |
| JPMorgan | 949,330 | 0 | 0 | 0 | For |
| Equitable | 182,774 | 168,810 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 333,424 | 0 | 0 | Against |
| Charles Schwab | 295,872 | 0 | 0 | 0 | For |
| Invesco | 0 | 291,363 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 232,300 | 0 | 0 | Against |
| SEI | 212,020 | 0 | 0 | 0 | For |
| Lincoln Financial | 168,180 | 2,209 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 161,956 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 150,000 | 0 | 0 | Against |
| Voya | 0 | 144,037 | 0 | 0 | Against |
| TIAA | 117,317 | 0 | 0 | 0 | For |
| ProShares | 0 | 71,514 | 0 | 0 | Against |
| ETF Series Solutions | 0 | 57,347 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 54,639 | 0 | 0 | Against |
| John Hancock | 0 | 41,953 | 0 | 0 | Against |
| Pacific Life | 41,846 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 0 | 40,200 | 0 | 0 | Against |
| Brighthouse | 0 | 36,454 | 0 | 0 | Against |
| New York Life | 29,740 | 0 | 0 | 0 | For |
| Nationwide | 1,065 | 28,557 | 0 | 0 | Against |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
MERSANA THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm The Company's stockholders approved Proposal 3”): 105,233,670 for, 323,020 against, per its Form 8-K filed 2024-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 122,361,236 outstanding shares: 86% for, 0.3% against (86% of the company cast a for/against vote).
The 42 asset managers below cast 99.9% of the shares they voted on this item FOR (19,717,879 for, 5,166 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,218,949 | 0 | 0 | 0 | For |
| BlackRock | 4,058,042 | 0 | 0 | 0 | For |
| State Street | 3,015,239 | 5,166 | 0 | 0 | For |
| Fidelity | 2,416,647 | 0 | 0 | 0 | For |
| JPMorgan | 949,330 | 0 | 0 | 0 | For |
| Equitable | 351,584 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 333,424 | 0 | 0 | 0 | For |
| Charles Schwab | 295,872 | 0 | 0 | 0 | For |
| Invesco | 291,363 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 232,300 | 0 | 0 | 0 | For |
| SEI | 212,020 | 0 | 0 | 0 | For |
| Lincoln Financial | 170,389 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 161,956 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 150,000 | 0 | 0 | 0 | For |
| Voya | 144,037 | 0 | 0 | 0 | For |
| TIAA | 117,317 | 0 | 0 | 0 | For |
| ProShares | 71,514 | 0 | 0 | 0 | For |
| ETF Series Solutions | 57,347 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 54,639 | 0 | 0 | 0 | For |
| John Hancock | 41,953 | 0 | 0 | 0 | For |
| Pacific Life | 41,846 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 40,200 | 0 | 0 | 0 | For |
| Brighthouse | 36,454 | 0 | 0 | 0 | For |
| New York Life | 29,740 | 0 | 0 | 0 | For |
| Nationwide | 29,622 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Ranked by the number of MERSANA THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 122,361,236 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | EcoR1 Capital, LLC | 15.83% |
| 2 | VR Adviser, LLC | 9.26% |
| 3 | Bain Capital Life Sciences Investors, LLC | 7.08% |
| 4 | State Street | 6.74% |
| 5 | BlackRock | 6.17% |
| 6 | Vanguard | 5.23% |
| 7 | Rock Springs Capital Management LP | 2.49% |
| 8 | Woodline Partners LP | 2.40% |
| 9 | Citadel | 2.16% |
| 10 | Fidelity | 2.15% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with EcoR1 Capital, LLC | 15.83% | DEF14A |
| Nextech Crossover I SCSp | 9.86% | 13G |
| Entities affiliated with Venrock Healthcare Capital Partners III, L.P. | 9.26% | DEF14A |
| Entities affiliated with Balyasny Asset Management L.P. | 7.93% | DEF14A |
| Andrew A. F. Hack, M.D., Ph.D. | 7.25% | DEF14A |
| Entities affiliated with Bain Capital Life Sciences | 7.08% | DEF14A |
| Blackrock, Inc. | 6.41% | DEF14A |
| SilverArc Capital Management, LLC | 5.25% | DEF14A |
| The Vanguard Group | 5.10% | 13G |
| State Street | 4.49% | 13F |
Percentages above are of 122,361,236 shares outstanding, as reported by MERSANA THERAPEUTICS INC. on its Form 10-Q dated 2024-05-03 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MERSANA THERAPEUTICS INC.’s 10-Q dated 2024-05-03. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At MERSANA THERAPEUTICS INC.'s shareholder meeting held 2024-06-11, in the 2023-2024 proxy season, 142 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 663 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: MERSANA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-11.
MERSANA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).